← Browse by Condition
Medical Condition

myelofibrosis mf

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for myelofibrosis mf sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myelofibrosis mf Clinical Trials

How many clinical trials are currently recruiting for myelofibrosis mf?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for myelofibrosis mf, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myelofibrosis mf?
myelofibrosis mf research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myelofibrosis mf clinical trial?
Eligibility criteria for myelofibrosis mf trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
1
Top Sponsors
Eilean Therapeutics 1 trial
Stanford University 1 trial
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT07529951 Phase 1
Recruiting
Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders
Enrollment
60 pts
Location
Australia, Uzbekista...
Sponsor
Eilean Therapeutics
View Trial →
NCT07302776 Phase 1
Recruiting
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Enrollment
50 pts
Location
United States
Sponsor
Stanford University
View Trial →
NCT07128381 Phase 1, Phase 2
Recruiting
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Enrollment
66 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

chronic myelomonocytic leukemia cmml (2) polycythemia vera pv (1) gvhd (1) hematopoietic cell transplantation hct (1) acute myeloid leukemia aml (1) myelodysplastic syndromes (1) chronic myeloid leukemia cml (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology